Renal & Urinary

Hypermagnesemia and hypomagnesemia: causes and treatment

Clinical Overview and When to Suspect Magnesium Disorders

— Chronic alcohol use disorder, malnutrition, refeeding syndrome

— Chronic diarrhea, malabsorption (celiac, short gut, bariatric surgery)

— Loop or thiazide diuretic use, PPI use >1 year

— Cisplatin, aminoglycosides, amphotericin B, tacrolimus/cyclosporine, cetuximab

— Refractory hypokalemia or hypocalcemia that won't correct

— New-onset arrhythmia (torsades, AF), tetany, seizures of unclear etiology

— CKD/ESRD on Mg-containing antacids, laxatives (milk of magnesia), or enemas

— Obstetric patients receiving IV MgSO₄ for preeclampsia or tocolysis

— Tumor lysis syndrome, rhabdomyolysis, adrenal insufficiency

— Patients with diminished reflexes, hypotension, or respiratory depression on telemetry

Board pearl: If you cannot correct hypokalemia or hypocalcemia despite aggressive repletion, check and replace magnesium first — Mg deficiency causes renal K⁺ wasting (via ROMK channel disinhibition) and impairs PTH secretion and end-organ response.

Step 3 management: In outpatient practice, screen for hypomagnesemia in patients on chronic PPIs plus diuretics — a classic Step 3 ambulatory combination that produces fatigue, cramps, and ECG changes that get misattributed to "anxiety" or "fibromyalgia." Order a serum Mg before escalating workup, and consider H2 blocker substitution if levels are persistently low despite oral repletion.

Magnesium (Mg²⁺) is the second most abundant intracellular cation; ~60% in bone, ~39% intracellular, only ~1% in serum — so serum Mg poorly reflects total body stores

Normal serum Mg: 1.7–2.2 mg/dL (0.7–1.0 mmol/L); regulation is primarily renal (thick ascending limb of Henle and distal convoluted tubule via TRPM6)

Hypomagnesemia (<1.7 mg/dL) — suspect in:

Hypermagnesemia (>2.2 mg/dL) — suspect in:

Presentation Patterns and Key History

— Tremor, fasciculations, muscle cramps, weakness

— Tetany, carpopedal spasm, positive Chvostek/Trousseau signs

— Seizures (especially in alcohol withdrawal, eclampsia)

— Vertical nystagmus, athetoid movements

— Palpitations, syncope from torsades de pointes or AF

— Apathy, depression, delirium, personality change

— 4–6 mg/dL: nausea, flushing, headache, lethargy, loss of deep tendon reflexes (earliest reliable sign)

— 6–10 mg/dL: somnolence, hypotension, bradycardia, ECG changes (prolonged PR, QRS, QT)

— >10 mg/dL: flaccid paralysis, respiratory muscle failure, complete heart block

— >12 mg/dL: cardiac arrest in diastole

— Diuretics (loop, thiazide), PPIs, alcohol intake quantified in drinks/week

— Diarrhea duration/volume, bariatric or bowel surgery

— Chemotherapy (cisplatin, cetuximab — EGFR inhibitors classically waste Mg)

— Antacid/laxative use, especially in elderly with constipation

— Pregnancy status (MgSO₄ infusion for preeclampsia/eclampsia or preterm labor)

— Family history of Gitelman or Bartter syndrome (young patient with cramps + hypokalemia + hypomagnesemia)

Key distinction: Both hypomagnesemia and hypocalcemia produce tetany and Chvostek/Trousseau signs — they coexist because Mg is required for PTH release and action. Check both ions; treating Ca²⁺ alone will fail.

Board pearl: Deep tendon reflex loss is the bedside vital sign during MgSO₄ infusion in obstetrics — nursing protocols mandate hourly DTR, respiratory rate, and urine output checks. If reflexes disappear, stop infusion and give IV calcium gluconate before drawing the level.

Hypomagnesemia symptoms are largely neuromuscular and cardiac, often overlapping with hypocalcemia/hypokalemia:

Hypermagnesemia symptoms progress in a dose-dependent cascade — memorize the threshold ladder:

Targeted history to obtain:

Physical Exam Findings and Hemodynamic Assessment

— Neuromuscular hyperexcitability: Chvostek sign (facial twitch on tapping CN VII), Trousseau sign (carpal spasm with BP cuff inflation >3 min)

— Hyperreflexia, clonus, tremor, fasciculations

— Vertical or rotary nystagmus — uncommon but specific

— Cardiovascular: irregular pulse (AF, PVCs, torsades), narrow pulse pressure if dehydrated

— Mental status: agitation, confusion, hallucinations (especially in alcohol withdrawal — overlap with DTs)

— Hyporeflexia → areflexia (patellar reflex is the standard bedside marker — disappears at Mg ~10 mg/dL)

— Flaccid weakness, decreased respiratory effort, shallow breathing

— Hypotension (Mg is a smooth muscle vasodilator and Ca²⁺ channel antagonist)

— Bradycardia, prolonged PR, widened QRS

— Flushing, warm skin, diaphoresis

— Pupillary changes minimal; mental status: lethargy → obtundation → coma

— Continuous telemetry for severe disturbances either direction

— Vital signs q15min during active IV repletion or active treatment of hypermagnesemia

— BP trend (hypotension is the cardinal hemodynamic finding of hypermagnesemia)

— Respiratory rate and effort — falling RR <12 in a Mg-toxic patient means prepare to intubate

— Urine output — oliguria worsens hypermagnesemia and signals need for dialysis

CCS pearl: On a CCS case of preeclampsia receiving MgSO₄, order "DTR, RR, urine output q1h" as a recurring action. If the exam shows absent reflexes or RR <12, the next orders are stop MgSO₄ infusion, IV calcium gluconate 1 g over 3 min, and continuous cardiac monitoring — in that exact sequence.

Board pearl: Trousseau sign is more specific than Chvostek for latent tetany (Chvostek has up to 25% false positives in healthy adults); always check both but weight Trousseau higher.

Hypomagnesemia exam findings:

Hypermagnesemia exam findings:

Hemodynamic assessment essentials:

Diagnostic Workup — Initial Labs, ECG, and Urine Studies

— Serum Mg²⁺ (total) — recognize that ionized Mg is more accurate but rarely available

— BMP: Na, K, Cl, HCO₃, BUN, Cr, glucose

— Serum Ca²⁺ and phosphate (often co-deranged)

— Albumin (low albumin lowers total Mg without lowering ionized fraction — mild factitious lows)

— PTH and 25-OH vitamin D if hypocalcemia coexists

— Prolonged QT, prolonged PR, widened QRS, ST depression, T-wave flattening/inversion

— U waves, premature beats, torsades de pointes

— Overlaps with hypokalemia ECG (often coexist)

— Prolonged PR, widened QRS, peaked T waves (early), then complete heart block, asystole

— 24-hour urine Mg >24 mg/day OR FE-Mg >2% during hypomagnesemia = renal wasting

— FE-Mg <2% = extrarenal loss (GI, redistribution, poor intake)

— FE-Mg formula: (Urine Mg × Plasma Cr) / (0.7 × Plasma Mg × Urine Cr) × 100 — the 0.7 corrects for the protein-bound fraction

— TSH (hyperthyroidism causes Mg wasting)

— Cortisol/aldosterone if mineralocorticoid excess suspected

— Stool studies if chronic diarrhea

— Genetic testing for Gitelman/Bartter in young patients with unexplained renal Mg wasting + metabolic alkalosis

Step 3 management: In a patient with refractory hypokalemia, order Mg level + urine Mg + urine K simultaneously — if FE-Mg >2% and urine K wasting also present, suspect a tubulopathy (Gitelman if low Ca excretion; Bartter if high), diuretic abuse, or aminoglycoside toxicity.

Board pearl: Don't trust a "normal" serum Mg in a patient with symptoms — order ionized Mg if available, or simply give an empiric repletion trial; only 1% of total body Mg is in serum.

Initial laboratory panel for any Mg disorder:

ECG findings — hypomagnesemia:

ECG findings — hypermagnesemia:

Urine magnesium studies distinguish renal from extrarenal loss when cause is unclear:

Other targeted tests based on clinical suspicion:

Diagnostic Workup — Advanced and Confirmatory Studies

— Ionized Mg²⁺ (gold standard but limited availability) — useful when albumin is abnormal or symptoms outpace serum level

— Magnesium loading test (rarely used outside research): IV 0.2 mEq/kg MgSO₄ over 4h; <70% recovered in 24h urine = total body Mg deficiency

— Genetic testing for tubulopathies (SLC12A3 = Gitelman; CLCNKB, KCNJ1, SLC12A1 = Bartter; CLDN16/19 = FHHNC with hypercalciuria/nephrocalcinosis; CASR = ADH; TRPM6 = HSH)

— Renal US if nephrocalcinosis suspected (FHHNC, chronic furosemide)

— Abdominal imaging if malabsorption — celiac serologies, fecal elastase, small bowel imaging

— Refeeding syndrome workup: monitor Mg, phosphate, K daily for 5–7 days when restarting nutrition after >5 days NPO or in severe malnutrition

— EGFR inhibitor (cetuximab, panitumumab) protocol: baseline + weekly Mg during therapy

— Cisplatin protocol: pre-treatment Mg level + post-cycle q2 weeks for up to 6 months (effect persists after drug stops)

— Repeat level, BUN/Cr, source review (laxatives, enemas, IV infusions, antacids)

— In neonates born to mothers on MgSO₄: cord Mg, monitor for 48h

Key distinction: Gitelman vs Bartter — both have hypokalemic metabolic alkalosis and renal Mg wasting, but Gitelman has hypocalciuria (mimics thiazide) and presents later in childhood/adulthood with cramps; Bartter has hypercalciuria (mimics furosemide) and presents earlier with growth failure and polyuria.

Board pearl: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is the only inherited Mg-wasting disorder that progresses to ESRD — patients need early nephrology referral, citrate to reduce stones, and eventual kidney transplant (which cures it, since defect is renal).

When initial workup is non-diagnostic, escalate to:

Imaging considerations:

Specific provocative scenarios:

Hypermagnesemia advanced workup is usually limited — the cause is clinical (renal failure + Mg exposure). Confirm with:

Risk Stratification and First-Line Management Logic

— Mild (1.4–1.7 mg/dL), asymptomatic: oral repletion, treat outpatient, address underlying cause

— Moderate (1.0–1.4 mg/dL), mild symptoms: oral repletion if tolerated, consider IV if GI cause

— Severe (<1.0 mg/dL) or symptomatic (seizure, arrhythmia, tetany): IV repletion, telemetry, admit

— Mild (2.2–4 mg/dL): stop Mg source, monitor, ensure renal function

— Moderate (4–7 mg/dL): IV fluids + loop diuretic if renal function adequate

— Severe (>7 mg/dL) or symptomatic: IV calcium gluconate, consider hemodialysis if renal failure or refractory

— Step 1: Assess severity and symptoms

— Step 2: Identify and stop offending agent (switch loop to K-sparing diuretic; stop PPI if possible; treat diarrhea)

— Step 3: Choose route — IV if symptomatic, oral if asymptomatic and outpatient

— Step 4: Co-repletion of K⁺ and Ca²⁺ as needed — Mg first

— Step 5: Address chronic loss with maintenance (amiloride for diuretic-induced wasting)

— Step 1: Stop all Mg-containing products (laxatives, antacids, IV infusions)

— Step 2: Cardiac monitor, IV access, assess airway

— Step 3: If symptomatic → IV calcium gluconate 1–2 g as antidote (antagonizes Mg at NMJ and cardiac membrane)

— Step 4: Promote excretion — normal saline + furosemide if renal function adequate

— Step 5: Hemodialysis if ESRD, severe symptoms, or failure of conservative measures

Step 3 management: In a stable outpatient with chronic mild hypomagnesemia from a PPI, the best long-term move is to deprescribe the PPI if indication is weak; if PPI is needed (Barrett's, refractory GERD), add oral Mg oxide or Mg glycinate and recheck in 2–4 weeks.

CCS pearl: For severe symptomatic hypermagnesemia in a dialysis patient, the case-closing order is emergent hemodialysis — calcium gluconate is only a temporizing bridge.

Severity stratification — hypomagnesemia:

Severity stratification — hypermagnesemia:

First-line decision tree — hypomagnesemia:

First-line decision tree — hypermagnesemia:

Pharmacotherapy — Repletion Regimens and Specifics

— Mg oxide 400–800 mg/day divided — cheapest, poorly absorbed, causes diarrhea

— Mg chloride sustained release (Slow-Mag) — better absorbed, less diarrhea

— Mg lactate (Mag-Tab SR) — well tolerated

— Mg glycinate or Mg gluconate — best GI tolerance

— Avoid Mg sulfate orally (cathartic)

— Dose: typically 240–1000 mg elemental Mg/day divided BID-QID; divided dosing reduces diarrhea

— Mild–moderate, asymptomatic: MgSO₄ 1–2 g IV over 1 hour

— Severe (<1.0 mg/dL) or symptomatic: MgSO₄ 2 g IV over 15 min, then 4–8 g over 12–24h

— Torsades de pointes: 2 g IV over 1–2 min, repeat in 5–15 min if needed

— Eclamptic seizure: 4–6 g IV load over 15–20 min, then 1–2 g/hour infusion

— Reduce dose 50% in renal impairment (CrCl <30)

— Amiloride or spironolactone: K-sparing diuretics also spare Mg — first-line for diuretic-induced or Gitelman-related Mg wasting

— Replace loop with thiazide in select cases or vice versa based on clinical context

— Address dietary intake: leafy greens, nuts, whole grains, legumes

— IV calcium gluconate 1–2 g (10–20 mL of 10% solution) over 5–10 min — antagonizes Mg effects at NMJ and myocardium; onset minutes

— 0.9% NaCl 150–200 mL/hr + furosemide 20–40 mg IV — promotes urinary Mg excretion (requires intact renal function)

— Hemodialysis with low-Mg dialysate for severe cases or renal failure

Board pearl: Replete Mg slowly even when severely low — rapid IV infusion of Mg causes flushing, hypotension, bradycardia, and even iatrogenic hypermagnesemia. Maximum rate 1 g/hour except in life-threatening arrhythmia or eclampsia.

Step 3 management: Renal tubular Mg handling means ~50% of an IV Mg dose is excreted in urine within 24 hours — chronic wasters need ongoing repletion or a K-sparing diuretic, not just a one-time IV bolus.

Oral magnesium preparations (for mild–moderate hypomagnesemia):

IV magnesium regimens:

Maintenance and chronic strategies:

Treatment of hypermagnesemia:

Expanded Pharmacology and Drug Interactions

— Loop diuretics (furosemide, bumetanide, torsemide) — inhibit paracellular Mg reabsorption in TAL

— Thiazides — inhibit DCT Mg reabsorption (less than loops)

— PPIs (≥1 year of use) — downregulate intestinal TRPM6, causes refractory hypomagnesemia; FDA black box-style warning

— Aminoglycosides, amphotericin B, foscarnet, pentamidine — direct tubular toxicity

— Cisplatin — persistent tubular damage; Mg loss can last months

— Calcineurin inhibitors (cyclosporine, tacrolimus) — DCT injury

— EGFR inhibitors (cetuximab, panitumumab) — block TRPM6; dose-limiting toxicity

— SGLT2 inhibitors — mild Mg loss (usually clinically insignificant)

— Mg-containing antacids (Maalox, Mylanta), laxatives (milk of magnesia, Mg citrate), enemas

— IV MgSO₄ (eclampsia, preterm labor, asthma, torsades)

— Lithium, theophylline overdose (mild)

— Mg potentiates neuromuscular blockers (succinylcholine, vecuronium) — prolonged paralysis risk

— Mg potentiates CCBs (additive hypotension)

— Oral Mg + bisphosphonates/tetracyclines/fluoroquinolones: chelation reduces absorption — separate by 2 hours

— Mg + digoxin: hypomagnesemia potentiates digoxin toxicity (replete Mg before assuming dig issue)

— In MI with arrhythmia, empiric Mg is not routine but is given if Mg <2 or for torsades

— In severe asthma, IV MgSO₄ 2 g over 20 min is adjunct for exacerbations not responding to bronchodilators

Board pearl: A patient on long-term omeprazole with cramps, paresthesias, and a normal K but low Ca that won't correct — the answer is PPI-induced hypomagnesemia. Switch to an H2 blocker (famotidine) and replete Mg.

Key distinction: Hypomagnesemia potentiates digoxin toxicity because both compete for the Na/K ATPase — always check Mg in a patient with possible dig toxicity, not just K.

Drugs that cause hypomagnesemia (memorize for board questions):

Drugs that cause hypermagnesemia:

Mg–drug interactions to know:

Special situations:

Special Populations — Elderly and Renal/Hepatic Impairment

— Polypharmacy is the dominant risk: combinations of PPI + loop diuretic + thiazide are extremely common

— Decreased dietary intake (chewing issues, fixed income, social isolation) compounds losses

— Falls and confusion may be the only symptoms — low threshold to check Mg in geriatric "failure to thrive"

— Constipation often prompts chronic Mg laxative use → hypermagnesemia risk, especially as GFR declines with age

— Brown bag medication review at every visit; deprescribe Mg-containing OTC products in CKD

— eGFR <30 mL/min: high risk for hypermagnesemia from any Mg-containing product (antacids, laxatives, IV infusions, enemas)

— Avoid milk of magnesia, Mg citrate bowel prep, MgSO₄ infusions unless absolutely necessary

— Use polyethylene glycol for constipation instead of Mg-based agents

— For colonoscopy bowel prep in CKD: PEG-based prep (GoLYTELY) is preferred over Mg citrate or sodium phosphate

— Repletion dose for hypomagnesemia: reduce by 50% in CrCl <30; recheck level q4–6h

— Standard dialysate Mg is 0.5–0.75 mmol/L; can adjust if patient is chronically high or low

— Hypermagnesemia in ESRD is treated with emergent hemodialysis

— Chronic alcohol use disorder is the prototype — combined poor intake, GI losses, and renal wasting (alcohol directly increases urinary Mg)

— Cirrhosis with diuretic therapy (spironolactone + furosemide for ascites) — monitor Mg with electrolytes q1–2 weeks

— Refeeding syndrome risk during hospitalization for alcohol-related illness

Step 3 management: In an elderly CKD patient admitted with constipation, do not order milk of magnesia — order PEG 17 g PO daily or lactulose. This is a high-yield Step 3 patient safety question (avoidable adverse event).

Board pearl: Alcohol use disorder patients have 3 mechanisms of Mg loss: poor intake, diarrhea/vomiting, and direct alcohol-induced renal Mg wasting. Always empirically replete Mg before starting glucose in suspected alcoholic ketoacidosis or before thiamine in Wernicke prophylaxis.

Elderly considerations:

Renal impairment:

Dialysis patients:

Hepatic impairment:

Special Populations — Pregnancy, Pediatrics, and Genetic Disorders

— MgSO₄ for preeclampsia/eclampsia: 4–6 g IV load over 20 min, then 1–2 g/hour infusion until 24h postpartum; goal serum Mg 4.8–8.4 mg/dL (therapeutic window)

— MgSO₄ for preterm labor (tocolysis): short-term use only

— MgSO₄ for fetal neuroprotection: <32 weeks gestation, reduces cerebral palsy risk

— Monitor: DTR q1h, RR, urine output (oliguria → drug accumulation)

— Antidote = IV calcium gluconate 1 g over 5–10 min for toxicity (loss of DTR, RR <12)

— Neonates born to mothers receiving prolonged MgSO₄ may have hypotonia, lethargy, respiratory depression — monitor 48h

— Bone abnormalities reported with prolonged maternal Mg therapy (>5–7 days)

— HSH (hypomagnesemia with secondary hypocalcemia): TRPM6 mutation; presents in infancy with seizures and tetany; lifelong high-dose oral Mg

— Bartter and Gitelman syndromes — Gitelman often diagnosed adolescent–adult, Bartter neonatal–childhood

— Refeeding in malnourished children (anorexia nervosa, neglect): monitor Mg/phos/K daily for first week

— Both restrictive and purging types cause hypomagnesemia

— Refeeding syndrome: introduce calories slowly (10–20 kcal/kg/day), supplement Mg, phos, K, thiamine before and during refeeding

Key distinction: Gitelman vs Bartter — Gitelman patients are typically older children/adults with cramps, fatigue, and hypocalciuria + hypomagnesemia; Bartter patients present earlier with growth failure, polyuria, polydipsia, and hypercalciuria with nephrocalcinosis. Both have hypokalemic metabolic alkalosis.

Board pearl: In an eclamptic patient on MgSO₄ who suddenly loses DTRs and has RR 10 — stop the infusion, give IV calcium gluconate 1 g, send stat Mg level. Do not delay calcium waiting for the lab result.

Step 3 management: Postpartum, continue MgSO₄ for 24 hours after delivery in preeclampsia/eclampsia — most postpartum seizures occur within this window.

Pregnancy — therapeutic Mg use:

Neonatal considerations:

Pediatric hypomagnesemia:

Adolescent eating disorders:

Complications and Adverse Outcomes

— Torsades de pointes — Mg is both a cause and a treatment; deficiency lengthens QT, repletion shortens it

— Atrial fibrillation — Mg deficiency is an under-recognized AF trigger, especially post-cardiac surgery

— Ventricular arrhythmias in acute MI — increased mortality risk

— Refractory hypokalemia — won't correct until Mg is replaced (Mg-deficient cells lose K via ROMK channels)

— Functional hypoparathyroidism — Mg required for PTH secretion AND end-organ response; severe hypoMg causes hypocalcemia that won't respond to Ca infusion alone

— Seizures, especially in alcohol withdrawal and eclampsia

— Increased mortality in ICU patients with hypomagnesemia (observational data)

— Osteoporosis with chronic hypomagnesemia (impaired vitamin D activation)

— Respiratory failure from diaphragmatic paralysis — primary cause of mortality

— Cardiac arrest (asystole, complete heart block) at Mg >12 mg/dL

— Profound hypotension — refractory to fluids; vasopressors may be needed

— Ileus — smooth muscle paralysis

— Hypocalcemia — Mg suppresses PTH at very high levels (paradoxical to hypomagnesemia effect)

— Neonatal hypotonia and respiratory depression from maternal MgSO₄

— Bowel prep with Mg citrate in CKD → severe hypermagnesemia, ICU admission, death

— Mg-containing antacid abuse in elderly with declining renal function

— Failure to monitor DTRs during obstetric MgSO₄ infusion

Board pearl: Mg infusion is first-line for torsades even if the serum Mg is normal — empiric 2 g IV over 1–2 min. Mg stabilizes the cardiac membrane independent of total body stores.

Key distinction: Hypomagnesemia causes hypocalcemia via two mechanisms (impaired PTH secretion + PTH resistance), while severe hypermagnesemia also causes hypocalcemia (suppresses PTH via CaSR activation) — Mg disorders are bidirectional disruptors of calcium homeostasis.

Hypomagnesemia complications:

Hypermagnesemia complications:

Iatrogenic harms:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Active arrhythmia (torsades, sustained VT, AF with hemodynamic instability)

— Active seizure or status epilepticus

— Mg <1.0 mg/dL with symptoms

— Severe alcohol withdrawal with DTs and hypomagnesemia

— Need for continuous IV infusion >12 hours

— Mg >7 mg/dL or any level with hypotension, bradycardia, hyporeflexia

— Respiratory depression (RR <12) or need for airway monitoring

— Failure of conservative measures (saline + furosemide)

— ESRD patient with severe symptoms requiring emergent dialysis

— Obstetric MgSO₄ toxicity not responding to calcium gluconate

— Symptomatic hypomagnesemia requiring IV repletion

— Refractory hypokalemia or hypocalcemia from hypomagnesemia

— Hypermagnesemia in CKD requiring monitoring without immediate dialysis need

— Eclampsia or severe preeclampsia (MFM service)

— Nephrology: ESRD with severe hypermagnesemia (urgent dialysis), unexplained renal Mg wasting, suspected tubulopathy

— Cardiology: hemodynamically unstable arrhythmia, torsades

— Endocrinology: refractory hypocalcemia + hypomagnesemia, suspected genetic tubulopathy

— Obstetrics/MFM: MgSO₄ infusion management

— Genetics: suspected Gitelman, Bartter, HSH, FHHNC

— Toxicology: massive ingestion of Mg-containing products

CCS pearl: In a CCS case of a CKD stage 4 patient who took a bottle of milk of magnesia for constipation and arrives obtunded with RR 8 and absent DTRs: orders should fire in this sequence — (1) IV access, (2) calcium gluconate 1 g IV, (3) airway support/intubation if needed, (4) stat dialysis consult, (5) 0.9% NaCl + furosemide bridge, (6) admit MICU.

Step 3 management: Do not discharge a patient with persistent symptomatic hypomagnesemia without confirming an outpatient repletion regimen, follow-up labs in 1–2 weeks, and review/discontinuation of contributing meds — failure to do so is a recognized transition-of-care failure.

Indications for ICU admission — hypomagnesemia:

Indications for ICU admission — hypermagnesemia:

Floor/inpatient admission criteria:

Consultations to consider:

Key Differentials — Same-Category Causes (Other Electrolyte Disorders)

— Tetany, Chvostek/Trousseau, prolonged QT, seizures

— Order both Ca and Mg together; replete Mg first because Mg deficiency causes hypocalcemia

— Ionized Ca is more accurate than total Ca when albumin is abnormal

— Weakness, cramps, arrhythmias (PVCs, U waves, torsades)

— Mg deficiency drives K wasting — refractory hypokalemia mandates Mg check

— Common shared causes: loop/thiazide diuretics, vomiting, diarrhea, alcohol use

— Co-occurs with hypomagnesemia in malnutrition/refeeding

— Causes weakness, rhabdomyolysis, respiratory failure

— Monitor and replete all three (Mg, K, phos) plus thiamine when refeeding

— Confusion and seizure overlap; check Na in any patient with neuromuscular symptoms

— Lethargy, weakness, constipation, polyuria

— Both cause CNS depression and decreased reflexes

— Differentiated by serum levels; both can coexist in malignancy or milk-alkali syndrome

— Metabolic alkalosis is common in Gitelman/Bartter (with hypomagnesemia)

— Metabolic acidosis in diarrhea-related Mg loss

— Respiratory alkalosis can lower ionized Ca and worsen tetany

Key distinction: A patient with carpopedal spasm, normal Ca, normal K, but persistent symptoms — check Mg. Conversely, a patient with low K and Ca not responding to repletion — check and replace Mg first.

Board pearl: Refeeding syndrome triad = hypophosphatemia + hypokalemia + hypomagnesemia, often with thiamine deficiency. Anticipate in any patient with BMI <16, >5 days minimal intake, or significant weight loss. Restart feeds at 10–15 kcal/kg/day with daily electrolytes for 5–7 days.

When a patient presents with neuromuscular symptoms (tetany, weakness, arrhythmia), always consider co-existing electrolyte abnormalities:

Hypocalcemia mimics hypomagnesemia almost exactly:

Hypokalemia overlaps with hypomagnesemia:

Hypophosphatemia in refeeding syndrome:

Hypernatremia/hyponatremia:

Hypercalcemia can mimic hypermagnesemia:

Acid-base disturbances:

Key Differentials — Other-Category Causes

— Hyperventilation syndrome: tetany, paresthesias, carpopedal spasm — anxiety-driven respiratory alkalosis lowers ionized Ca

— Seizure disorders: idiopathic epilepsy, alcohol withdrawal, eclampsia

— Multiple sclerosis, peripheral neuropathy: paresthesias, cramps

— ALS, myasthenia gravis: weakness, fasciculations

— Long QT syndrome (congenital): torsades de pointes with normal electrolytes — check family history, baseline ECG

— Drug-induced QT prolongation: methadone, ondansetron, fluoroquinolones, antipsychotics, antiemetics

— Ischemic arrhythmias: rule out MI in any new VT/torsades

— Primary hyperparathyroidism: hypercalcemia → weakness, polyuria, constipation

— Hyperaldosteronism: hypokalemia, alkalosis, hypertension — overlaps with Mg wasting

— Hypothyroidism/hyperthyroidism: thyrotoxicosis increases urinary Mg loss

— Adrenal insufficiency: weakness, hypotension — co-existing electrolyte derangements

— Opioid toxicity: respiratory depression, hypotension, but pupils miotic; check naloxone response

— Benzodiazepine overdose: sedation, hyporeflexia, but normal Mg

— Botulism, Guillain-Barré, myasthenic crisis: flaccid weakness with normal labs

— Severe hypercalcemia: lethargy, weakness, ileus

— Sepsis with shock: hypotension, lactic acidosis

— Lithium, theophylline, organophosphate poisoning

— Ethylene glycol/methanol — anion gap acidosis with hypocalcemia

Step 3 management: A patient with new torsades and a normal Mg — still give empiric IV MgSO₄ 2 g, then look for QT-prolonging drugs (review med list including outpatient antiemetics, antibiotics, psych meds), congenital long QT, and treat reversible causes.

Board pearl: In alcohol withdrawal, the seizure could be from withdrawal itself, hypomagnesemia, hypoglycemia, or head trauma — empirically address all (thiamine, glucose, Mg, neuro exam, head CT if focal signs).

Neurologic mimics of hypomagnesemia symptoms:

Cardiac mimics:

Endocrine mimics:

Mimics of hypermagnesemia presentation:

Toxicologic differentials:

Secondary Prevention and Long-Term Management

— Diuretic-induced wasting: switch to or add a K-sparing diuretic (amiloride preferred for Mg sparing); minimize loop dose

— PPI-induced hypomagnesemia: deprescribe PPI if possible; switch to H2 blocker (famotidine); if PPI essential, use lowest effective dose + oral Mg supplement

— Chronic diarrhea: treat IBD, celiac, bile acid malabsorption; consider cholestyramine for bile acid; loperamide for refractory functional diarrhea

— Alcohol use disorder: counseling, naltrexone or acamprosate, nutritional rehab, regular Mg + multivitamin

— EGFR inhibitor / cisplatin: scheduled IV Mg repletion every 1–2 weeks during treatment; oral Mg often inadequate

— Gitelman syndrome: lifelong oral Mg and K supplementation; amiloride or spironolactone; high-salt diet

— 240–500 mg elemental Mg/day divided BID-TID

— Mg glycinate or sustained-release Mg chloride best tolerated for chronic use

— Take with food to reduce diarrhea

— Separate from tetracyclines, fluoroquinolones, bisphosphonates by 2 hours

— Patient education: avoid all Mg-containing OTC products (milk of magnesia, Mg citrate, Mg-containing antacids like Maalox)

— Substitute: PEG 3350 for constipation, calcium carbonate for antacid

— Update medication list and pharmacy alerts in CKD patients

— Counsel before bowel prep procedures: use PEG-based preps

— Leafy greens (spinach, kale), nuts (almonds, cashews), seeds (pumpkin), whole grains, legumes, dark chocolate, avocado

Step 3 management: A CKD patient discharged after constipation needs an explicit medication reconciliation: remove Mg-containing laxatives/antacids from the home med list, document substitution (PEG, calcium carbonate), and counsel patient and family — this is a board-tested transition-of-care intervention.

Board pearl: In post-cardiac surgery AF prevention, prophylactic Mg supplementation reduces incidence — many institutions protocol Mg level >2 mg/dL in the perioperative window.

Once acutely corrected, prevent recurrence by addressing root cause:

Maintenance oral Mg dosing:

Hypermagnesemia secondary prevention:

Dietary counseling for chronic hypomagnesemia:

Follow-Up, Monitoring Parameters, and Counseling

— Repeat serum Mg, K, Ca, phos, Cr at 1–2 weeks after starting oral repletion

— Reassess every 3–6 months if cause is chronic and stable

— If on chronic PPI: annual Mg, especially with concurrent diuretic

— If on cisplatin/cetuximab: weekly during therapy, every 2–4 weeks for 6 months after

— If on chronic loop diuretic: BMP + Mg every 3–6 months

— Continuous telemetry until level normalized

— Serum Mg q4–6h during active infusion

— DTRs, BP, RR every 1–2 hours

— Watch for iatrogenic hypermagnesemia, especially in CKD

— Mg level q2–4h until <4 mg/dL

— Continuous ECG and pulse oximetry

— Strict urine output (Foley if needed) to assess renal clearance

— Hourly DTR, RR, BP

— Symptoms to watch for that warrant return: muscle cramps, palpitations, seizures, numbness/tingling, severe weakness

— Medication adherence — divided doses to reduce diarrhea

— Avoid OTC Mg products if CKD

— Limit alcohol, optimize diet

— Don't stop diuretic without provider input even if cramping

— Alcohol use disorder treatment referral with concurrent Mg counseling

— Nutrition consult for malnutrition, refeeding, eating disorders, bariatric patients

— Dietician referral for chronic GI loss or Gitelman/Bartter

CCS pearl: Order a follow-up Mg level in 2 weeks as a discharge action on CCS cases of hypomagnesemia treated outpatient — this captures the longitudinal management point graders look for.

Step 3 management: In bariatric surgery patients (especially Roux-en-Y gastric bypass), screen Mg annually as part of the lifelong micronutrient panel (also B12, iron, vitamin D, calcium, thiamine, folate). Chronic deficits develop years out and present with insidious neuromuscular symptoms.

Outpatient follow-up after hypomagnesemia correction:

Monitoring during acute IV repletion:

Monitoring during hypermagnesemia treatment:

Patient counseling points:

Rehab/lifestyle adjuncts:

Ethical, Legal, and Patient Safety Considerations

— Independent double-check required for MgSO₄ infusion preparation and pump programming

— Standard order sets specify load + maintenance dose, monitoring frequency (DTR, RR, UOP q1h), and antidote (calcium gluconate at bedside)

— Smart pump dose-error reduction software

— Common error: continuing MgSO₄ after delivery beyond 24h without indication, or in oliguric postpartum patients → accumulation toxicity

— Discharging a CKD patient on a Mg-containing laxative or antacid is an avoidable adverse event — explicit medication reconciliation required

— Failing to communicate ongoing IV Mg repletion plan to the next provider can lead to abrupt cessation and rebound symptomatic hypomagnesemia

— Outpatient follow-up labs must be ordered before discharge, not deferred to "primary care"

— Eclampsia patients on MgSO₄ may have altered mental status — consent for emergency interventions follows emergency doctrine; document inability to consent and obtain surrogate where possible

— Bowel prep selection: in CKD, document the choice of PEG over Mg-based prep and the rationale

— Recurrent hypermagnesemia in an elderly patient from caregiver-administered laxatives may raise concern for elder neglect/abuse — assess capacity, home situation, and consider Adult Protective Services referral if warranted

— Iatrogenic hypermagnesemia (e.g., from inappropriate Mg-citrate bowel prep in CKD) requires honest disclosure to patient/family per AMA ethics and institutional policy

— EHR alerts for Mg-containing products in patients with eGFR <30

— Standard order sets for repletion regimens with dose adjustment for renal function

— Pharmacist verification for high-alert IV Mg infusions

Board pearl: Eclampsia-related MgSO₄ infusions are a sentinel-event-prone drug — independent double-checks, smart pumps, and bedside calcium gluconate are now standard of care; absence of these on a board scenario is a quality-improvement red flag.

Step 3 management: When a patient is harmed by an iatrogenic electrolyte error, the correct step is honest disclosure, root cause analysis, and system-level fix (not blame of the individual ordering clinician) — this aligns with patient safety frameworks tested on Step 3.

Patient safety in obstetric MgSO₄ administration (Joint Commission-flagged high-alert medication):

Transitions of care risks:

Informed consent issues:

Mandatory reporting and elder safety:

Disclosure of adverse events:

Quality improvement angles:

High-Yield Associations and Rapid-Fire Clinical Facts

— Diuretics (loop, thiazide), Diarrhea

— Intake poor (alcoholism, malnutrition), Iatrogenic (PPI, cisplatin, cetuximab, aminoglycosides)

— Renal wasting (Gitelman, Bartter, tubular injury)

— Tubular dysfunction, Transfusion (citrate chelation, transient)

— CKD/ESRD + Mg load (laxative, antacid, enema, IV)

— Iatrogenic obstetric MgSO₄

— Tumor lysis, rhabdomyolysis, adrenal insufficiency, hypothermia, DKA

Board pearl: "Magnesium is the forgotten cation" — if Step 3 gives you persistent K or Ca abnormalities, persistent arrhythmia, or persistent tetany, the answer is almost always check the magnesium.

Key distinction: Hypomagnesemia causes hyperreflexia + tetany; hypermagnesemia causes hyporeflexia + paralysis. The reflex exam is your single best bedside discriminator.

Mg is required for: PTH secretion, PTH end-organ action, Na/K ATPase function, K homeostasis, neuromuscular junction stability, cardiac membrane stabilization, ATP-dependent reactions

Hypomagnesemia causes (mnemonic — "DIRT"):

Hypermagnesemia causes:

Refractory hypokalemia → check Mg

Refractory hypocalcemia → check Mg

Torsades de pointes → empiric IV Mg 2 g over 1–2 min, even if Mg "normal"

Hypermagnesemia antidote → IV calcium gluconate

Loss of DTRs is the bedside marker of clinically significant hypermagnesemia

Patellar reflex first to disappear; respiratory muscle paralysis next

Cisplatin Mg wasting can last months after drug discontinuation

EGFR inhibitors (cetuximab, panitumumab) cause TRPM6 dysfunction in DCT

Gitelman = hypocalciuria + hypomagnesemia; Bartter = hypercalciuria + hypomagnesemia

PPIs cause hypomagnesemia after ~1 year of use; refractory to oral repletion until PPI is stopped

Alcohol has three mechanisms of Mg loss (intake, GI, renal)

Refeeding syndrome = hypo-phos + hypo-K + hypo-Mg + thiamine deficiency

Mg potentiates neuromuscular blockers, CCBs, opioids

Mg + digoxin → hypomagnesemia worsens dig toxicity

Eclampsia MgSO₄ therapeutic range: 4.8–8.4 mg/dL

Board Question Stem Patterns

Step 3 management: Step 3 favors management decision-points over diagnosis — expect questions asking "what is the next step" with answer choices including "check Mg," "give IV Mg," "stop offending drug," or "schedule outpatient follow-up labs."

Board pearl: When a stem mentions "despite adequate K replacement" or "calcium gluconate did not improve symptoms," the missing electrolyte is magnesium.

Stem 1 — Refractory hypokalemia: 55F on furosemide for HF, K is 3.0 despite 80 mEq KCl/day for 3 days. → Answer: check and replete Mg first

Stem 2 — PPI-induced: 62M on omeprazole 5 years, presents with paresthesias, cramps; Ca 8.0, Mg 1.2, K 3.4. → Answer: stop PPI, replete Mg; long-term plan = switch to H2 blocker

Stem 3 — Eclampsia toxicity: 28F at 36 weeks with severe preeclampsia on MgSO₄, RR 10, areflexia. → Answer: stop infusion + IV calcium gluconate 1 g

Stem 4 — CKD + bowel prep: 70M with CKD stage 4 received Mg citrate prep, now lethargic, hypotensive, bradycardic. → Answer: IV calcium gluconate; emergent hemodialysis if ESRD or refractory

Stem 5 — Torsades: Patient on methadone develops torsades; Mg 2.0. → Answer: IV MgSO₄ 2 g empirically regardless of level

Stem 6 — Chronic alcohol use: 45M with DTs has Mg 1.0, K 3.0, phos 1.5, glucose 70. → Answer: thiamine before glucose, replete Mg + K + phos; monitor refeeding

Stem 7 — Gitelman: 22F with chronic cramps, polyuria; K 2.8, Mg 1.3, metabolic alkalosis, low urine Ca. → Answer: Gitelman syndrome, treat with oral Mg + K, amiloride or spironolactone

Stem 8 — Bartter: 8M with growth failure, polyuria; K 2.5, Mg 1.4, alkalosis, high urine Ca, nephrocalcinosis on US. → Answer: Bartter syndrome

Stem 9 — Cisplatin nephrotoxicity: 60M on cisplatin for lung CA, cramps; Mg 1.1. → Answer: scheduled IV Mg repletion during and after therapy

Stem 10 — Refeeding: Anorexic patient day 3 of refeeding, weakness, arrhythmia; Mg 1.0, phos 1.2, K 2.8. → Answer: slow caloric advancement; replete Mg/phos/K/thiamine

Stem 11 — Digoxin toxicity: Elderly on dig + furosemide, nausea, yellow vision; Mg 1.3, K 3.2. → Answer: replete Mg and K alongside dig management

One-Line Recap

Rapid recap bullets:

Board pearl: Replete magnesium before potassium or calcium when all three are low — without adequate Mg, K and Ca repletion fail.

Step 3 management: Every Mg disorder management plan must include (1) acute correction, (2) cause identification and removal, (3) maintenance strategy, (4) outpatient follow-up labs in 1–2 weeks, and (5) medication reconciliation — failure of any one component is a recognized board-tested gap in care.

Bottom line: Magnesium homeostasis is regulated by the renal tubule, deficiency causes neuromuscular hyperexcitability and refractory K/Ca abnormalities (replete Mg first), while excess causes hyporeflexia, hypotension, and respiratory paralysis treated with IV calcium gluconate and (if needed) hemodialysis.

Hypomagnesemia = hyperreflexia, tetany, torsades, refractory hypoK/hypoCa → causes are DIRT (Diuretics/Diarrhea, Intake/Iatrogenic [PPI, cisplatin, cetuximab, aminoglycosides], Renal wasting, Tubular injury); treat with oral Mg if mild/stable, IV MgSO₄ 1–2 g over 1 hr for moderate, 2 g over 15 min for severe or torsades; address root cause (deprescribe PPI, add amiloride, treat alcohol use)

Hypermagnesemia = hyporeflexia → respiratory depression → cardiac arrest; almost always CKD + Mg exposure (laxative, antacid, IV) or obstetric MgSO₄; treat with stop the source, IV calcium gluconate 1–2 g as antidote, saline + furosemide if renal function allows, hemodialysis for ESRD or severe/refractory cases

Always check Mg in refractory hypokalemia, refractory hypocalcemia, refractory arrhythmia (especially torsades), digoxin toxicity, alcohol withdrawal, and refeeding syndrome — Mg is the "forgotten cation" that gates correction of other electrolytes

Step 3 transition-of-care priority: in CKD patients, eliminate all Mg-containing OTC products (milk of magnesia, Mg citrate, Maalox) and substitute PEG-based laxatives and calcium-based antacids; in chronic PPI/diuretic users, schedule Mg monitoring every 6–12 months